Multiantigenic Nanovaccines: Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size (Adv. Funct. Mater. 49/2019) | Zendy

Li Shengxian | Zendy; Feng Xiangru | Zendy; Wang Jixue | Zendy; Xu Weiguo | Zendy; Islam Mohammad Ariful | Zendy; Sun Tianmeng | Zendy; Xie Zhigang | Zendy; Wang Chunxi | Zendy; Ding Jianxun | Zendy; Chen Xuesi | Zendy

Premium

Multiantigenic Nanovaccines: Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size (Adv. Funct. Mater. 49/2019)

Author(s) -

Li Shengxian,

Feng Xiangru,

Wang Jixue,

Xu Weiguo,

Islam Mohammad Ariful,

Sun Tianmeng,

Xie Zhigang,

Wang Chunxi,

Ding Jianxun,

Chen Xuesi

Publication year - 2019

Publication title -

advanced functional materials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.069

H-Index - 322

eISSN - 1616-3028

pISSN - 1616-301X

DOI - 10.1002/adfm.201970336

Subject(s) - materials science , imiquimod , cancer immunotherapy , immunity , lymph , cross presentation , hela , nanotechnology , cancer research , immunotherapy , antigen presentation , immune system , t cell , cell , biology , immunology , medicine , biochemistry , psychiatry

In article number 1903391, Jianxun Ding and co‐workers develop three multiantigenic nanovaccines of different sizes for cancer immunotherapy, which are composed of various imiquimod‐loaded poly(lactic‐co‐glycolic acid) nanoparticles and a cancer cell membrane coating. The smallest nanovaccine shows rapid migration to the draining lymph nodes, achieves efficient antigen presentation to T lymphocytes, and induces antitumor immunity.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research